Among them, anti-bone resorptive agents, such as bisphosphonate and anti-RANKL antibody (Denosumab), markedly inhibit the pathogenic bone resorption in osteoporosis and cancer bone metastasis [48,49,50]. This evidence concerns the gene TNFSF11 and cancer.